Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DESP +10.8%, CWCO +7.2%, BABA +3.1%, AEG +2.7%, POST +1%
Other news:
- RCAT +10.9% (files $100 mln mixed shelf securities offering; also files for 13.55 mln offering by selling shareholders)
- MNOV +9% (Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver)
- ZLAB +7.9% (prices offering of 7,843,137 ADSs at $25.50 per ADS)
- EVO +7.6% (HALO confirms it made bid to acquire EVO)
- DPZ +7% (Berkshire Hathaway takes new position)
- POOL +5.8% (Berkshire Hathaway takes new position)
- ALMS +5% (presents data highlighting ESK-001)
- PLTR +2.7% (to move to Nasdaq from NYSE)
- ZURA +2.5% (submits protocol to FDA for Phase 2 study of tibulizumab)
- CDXS +2.1% (unveils pioneering enzymatic synthesis data)
- AUPH +1.8% (Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS)
- NKE +1.2% (raises quarterly dividend by 8%)
- SNY +1% (Regeneron Pharma and Sanofi (SNY) announces the FDA accepts renewed submission of Dupixent sBLA)
- SNDL +1% (renews share repurchase program)